Skip to main content

From The Newsrooms

Background: Major depressive disorder (MDD) includes a metabolic component that is associated with poor antidepressant response, and correction may improve core symptoms. This analysis assessed the effect of L-methylfolate 15 mg as an adjunct to…
The paradigm used for neuropsychiatric diagnosis and patient management is primarily based upon clinical interviews to stratify patients within adopted classifications. This paradigm has the caveat of not including information derived from…
Background: Aripiprazole, olanzapine, and quetiapine are indicated as adjunctive agents in the treatment of major depressive disorder (MDD). Objective: To examine real-world data on medical costs and utilization in patients with MDD treated…
Background: Aripiprazole and other atypical antipsychotics are important treatment options for BPD patients. Objective: To summarize real-world data of medical costs and utilization in patients with BPD treated with aripiprazole, olanzapine,…
Objective: To compare treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder newly treated with quetiapine IR (QTP-IR) or XR (QTP-XR). Methods: Observational, retrospective cohort study utilizing HealthCore…
Background/Objectives: Pseudobulbar affect (PBA) is an under-recognized and undertreated neurological disorder of emotional expression occurring secondary to a variety of neurological disorders. PBA is characterized by frequent, involuntary…
Back to Top